Endo Operations patent expiration
1. Adrenalin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295657 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US9119876 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US10130592 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US11083698 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US10653646 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US11207280 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 December, 2012
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis; To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock
Dosage: SOLUTION
How can I launch a generic of ADRENALIN before it's drug patent expiration?
More Information on Dosage
ADRENALIN family patents
2. Aveed patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO OPERATIONS | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
| US8338395 | ENDO OPERATIONS | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 05, 2017 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE
How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage
AVEED family patents
3. Ephedrine Sulfate patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869845 | ENDO OPERATIONS | Ephedrine compositions and methods |
Jan, 2040
(15 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of EPHEDRINE SULFATE before it's drug patent expiration?
More Information on Dosage
EPHEDRINE SULFATE family patents
4. Fortesta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6319913 | ENDO OPERATIONS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
| US6579865 | ENDO OPERATIONS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 29, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 December, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED
How can I launch a generic of FORTESTA before it's drug patent expiration?
More Information on Dosage
FORTESTA family patents
5. Frova patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962501 | ENDO OPERATIONS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(10 years ago) | |
| US5616603 | ENDO OPERATIONS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(10 years ago) | |
| US5637611 | ENDO OPERATIONS | Medicaments |
Jun, 2014
(10 years ago) | |
| US5827871 | ENDO OPERATIONS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(8 years ago) | |
| US5464864 | ENDO OPERATIONS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(8 years ago) | |
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: TABLET
How can I launch a generic of FROVA before it's drug patent expiration?
More Information on Dosage
FROVA family patents
6. Megace Es patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6592903 | ENDO OPERATIONS | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US7101576 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
| US9101549 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
| US9040088 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
| US9101540 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
| US9107827 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION
How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage
MEGACE ES family patents
7. Nascobal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940714 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(6 months ago) | |
| US7404489 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(5 months ago) | |
| US9415007 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(a month ago) | |
| US7879349 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) | |
| US7229636 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) | |
| US8003353 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) | |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED
How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage
NASCOBAL family patents
8. Opana Er patent expiration
OPANA ER's oppositions filed in EPO
OPANA ER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8871779 | ENDO OPERATIONS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958456 | ENDO OPERATIONS | Controlled release formulation (albuterol) |
Sep, 2013
(11 years ago) | |
| US5662933 | ENDO OPERATIONS | Controlled release formulation (albuterol) |
Sep, 2013
(11 years ago) | |
| US8329216 | ENDO OPERATIONS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 7 months ago) | |
| US7276250 | ENDO OPERATIONS | Sustained release formulations of oxymorphone |
Feb, 2023
(1 year, 7 months ago) | |
| US8309112 | ENDO OPERATIONS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(1 year, 7 months ago) | |
| US8808737 | ENDO OPERATIONS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(2 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
9. Sumavel Dosepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5891086 | ENDO OPERATIONS | Needle-less injector |
Jul, 2014
(10 years ago) | |
| US6681810 | ENDO OPERATIONS | Filling device for a needleless injector cartridge |
Dec, 2015
(8 years ago) | |
| US6174304 | ENDO OPERATIONS | Filling device for a needless injector cartridge |
Dec, 2015
(8 years ago) | |
| US5957886 | ENDO OPERATIONS | Spring-Powered dispensing device |
Mar, 2016
(8 years ago) | |
| US6251091 | ENDO OPERATIONS | Needleless injector drug capsule and filling method |
Dec, 2016
(7 years ago) | |
| US6135979 | ENDO OPERATIONS | Spring-powered dispensing device for medical purposes |
Mar, 2017
(7 years ago) | |
| US6280410 | ENDO OPERATIONS | Method of filling a drug capsule and article produced thereby |
Mar, 2017
(7 years ago) | |
| US8343130 | ENDO OPERATIONS | Needleless injector |
Oct, 2022
(1 year, 10 months ago) | |
| US8491524 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 9 months ago) | |
| US8241244 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 9 months ago) | |
| US8267903 | ENDO OPERATIONS | Casing |
Mar, 2023
(1 year, 5 months ago) | |
| US8118771 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(1 year, 29 days ago) | |
| US8287489 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Dec, 2024
(2 months from now) | |
| US8241243 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Dec, 2025
(1 year, 3 months from now) | |
| US7901385 | ENDO OPERATIONS | Casing |
Jul, 2026
(1 year, 10 months from now) | |
| US7776007 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Nov, 2026
(2 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
SUMAVEL DOSEPRO family patents
10. Supprelin La patent expiration
SUPPRELIN LA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062652 | ENDO OPERATIONS | Compositions and methods for treating precocious puberty |
Jun, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 03, 2014 |
Drugs and Companies using HISTRELIN ACETATE ingredient
Market Authorisation Date: 03 May, 2007
Treatment: Method of treatment of children with central precocious puberty
Dosage: IMPLANT
More Information on Dosage
SUPPRELIN LA family patents
11. Testim patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8178518 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7935690 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608605 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608606 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US8063029 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608609 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608608 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608607 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7608610 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
| US7320968 | ENDO OPERATIONS | Pharmaceutical composition |
Jan, 2025
(4 months from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 31 October, 2002
Treatment: Method for administration of testosterone
Dosage: GEL
How can I launch a generic of TESTIM before it's drug patent expiration?
More Information on Dosage
TESTIM family patents
12. Vasostrict patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9981006 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9962422 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9925233 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9925234 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9968649 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9974827 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US10010575 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9375478 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744239 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744209 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9687526 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9919026 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9750785 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9937223 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION
How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage
VASOSTRICT family patents